Verastem, Inc. (VSTM)
NASDAQ: VSTM · Real-Time Price · USD
5.19
0.00 (0.00%)
Jun 18, 2025, 4:00 PM - Market closed
Verastem Employees
Verastem had 78 employees as of December 31, 2024. The number of employees increased by 5 or 6.85% compared to the previous year.
Employees
78
Change (1Y)
5
Growth (1Y)
6.85%
Revenue / Employee
$128,205
Profits / Employee
-$1,908,679
Market Cap
285.19M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
VSTM News
- 17 days ago - Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) Inhibitor - Business Wire
- 22 days ago - Verastem Oncology to Present at the Jefferies Global Healthcare Conference - Business Wire
- 4 weeks ago - Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in Frontline Metastatic Pancreatic Ductal Adenocarcinoma - Business Wire
- 4 weeks ago - Tempus Announces a Collaboration with Verastem to Develop CDx for First-Ever FDA-Approved KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer Combination Treatment - Business Wire
- 5 weeks ago - Verastem Oncology Reports First Quarter 2025 Financial Results and Highlights Recent Business Updates - Business Wire
- 6 weeks ago - FDA Approves the AVMAPKI™ FAKZYNJA™ Combination Therapy as the First-Ever Treatment for Adult Patients with KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer - Business Wire
- 6 weeks ago - U.S. FDA approves Verastem's cancer therapy - Reuters
- 7 weeks ago - Verastem Oncology to Present at Upcoming Investor Conferences - Business Wire